Raymond James & Associates Boosts Holdings in West Pharmaceutical Services, Inc. (NYSE:WST)

Raymond James & Associates grew its position in shares of West Pharmaceutical Services, Inc. (NYSE:WST) by 2.3% in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 77,545 shares of the medical instruments supplier’s stock after buying an additional 1,709 shares during the quarter. Raymond James & Associates owned 0.11% of West Pharmaceutical Services worth $23,276,000 as of its most recent filing with the SEC.

Other hedge funds also recently made changes to their positions in the company. Pitcairn Co. raised its holdings in West Pharmaceutical Services by 3.4% during the first quarter. Pitcairn Co. now owns 875 shares of the medical instruments supplier’s stock worth $346,000 after purchasing an additional 29 shares in the last quarter. Clearbridge Investments LLC boosted its holdings in West Pharmaceutical Services by 0.7% in the 1st quarter. Clearbridge Investments LLC now owns 4,495 shares of the medical instruments supplier’s stock valued at $1,779,000 after purchasing an additional 31 shares in the last quarter. Ballentine Partners LLC increased its position in West Pharmaceutical Services by 4.7% during the 2nd quarter. Ballentine Partners LLC now owns 742 shares of the medical instruments supplier’s stock worth $244,000 after purchasing an additional 33 shares during the period. RFG Advisory LLC raised its stake in shares of West Pharmaceutical Services by 2.3% during the 2nd quarter. RFG Advisory LLC now owns 1,499 shares of the medical instruments supplier’s stock worth $494,000 after buying an additional 34 shares in the last quarter. Finally, Bleakley Financial Group LLC lifted its holdings in shares of West Pharmaceutical Services by 1.9% in the 1st quarter. Bleakley Financial Group LLC now owns 2,174 shares of the medical instruments supplier’s stock valued at $860,000 after buying an additional 41 shares during the period. Institutional investors and hedge funds own 93.90% of the company’s stock.

Insiders Place Their Bets

In other news, VP Charles Witherspoon sold 1,029 shares of West Pharmaceutical Services stock in a transaction that occurred on Monday, August 19th. The shares were sold at an average price of $300.00, for a total transaction of $308,700.00. Following the completion of the sale, the vice president now directly owns 1,478 shares in the company, valued at approximately $443,400. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.53% of the stock is currently owned by company insiders.

West Pharmaceutical Services Trading Up 15.4 %

Shares of WST stock opened at $330.65 on Friday. The business’s fifty day moving average price is $300.36 and its 200 day moving average price is $322.86. The firm has a market capitalization of $23.99 billion, a PE ratio of 47.03, a P/E/G ratio of 10.21 and a beta of 1.01. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.34 and a quick ratio of 1.68. West Pharmaceutical Services, Inc. has a 1-year low of $265.00 and a 1-year high of $413.70.

West Pharmaceutical Services (NYSE:WST) last posted its quarterly earnings results on Thursday, July 25th. The medical instruments supplier reported $1.52 earnings per share for the quarter, missing analysts’ consensus estimates of $1.74 by ($0.22). The company had revenue of $702.10 million for the quarter, compared to analyst estimates of $729.36 million. West Pharmaceutical Services had a return on equity of 19.17% and a net margin of 18.25%. The business’s revenue for the quarter was down 6.9% compared to the same quarter last year. During the same period last year, the company earned $2.11 earnings per share. As a group, sell-side analysts forecast that West Pharmaceutical Services, Inc. will post 6.42 EPS for the current fiscal year.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.